Author

Marco DiBonaventura 1

1 Pfizer Inc,New York,United States

Item-level improvements in inflammatory bowel disease questionnaire scores in patients with ulcerative colitis treated with tofacitinib induction therapy

Marla C. Dubinsky, Marco DiBonaventura, Haiyun Fan, Andrew G. Bushmakin, Joseph C. Cappelleri, Eric Maller, Andrew J. Thorpe, Leonardo Salese, Julian Panés

EFFICACY OF TOFACITINIB AND BIOLOGICS AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS

David T. Rubin, Ajibade O Ashaye, Younan Zhang, Kyle Fahrbach, Andreas Freitag, Cem Kayhan, Christoph Lohan, Joseph C. Cappelleri, Marco DiBonaventura

THE ASSOCIATION BETWEEN DISEASE ACTIVITY AND PATIENT-REPORTED OUTCOMES IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS IN EUROPE

Alessandro Armuzzi, Miriam Tarallo, Marco DiBonaventura, Danielle Bargo, James Lucas, Daniel Bluff, Ben Hoskin, Leonardo Salese, Joseph C. Cappelleri, Giovanni Gigante

Living with ulcerative colitis in Germany: estimating the frequency and extent of dose escalations among patients with moderate to severe ulcerative colitis

Axel Dignass, John Waller, Joseph C. Cappelleri, Irene Modesto, Agnes Kisser, Lena Dietz, Marco DiBonaventura, Robert Wood, Danielle Bargo

Living with ulcerative colitis in Germany: exploring concomitant steroid and immunosuppressant use among patients with moderate to severe ulcerative colitis

Axel Dignass, John Waller, Joseph C. Cappelleri, Irene Modesto, Agnes Kisser, Lena Dietz, Marco DiBonaventura, Robert Wood, Danielle Bargo

TREATMENT PATTERNS AMONG PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS IN WESTERN EUROPE

Alessandro Armuzzi, Miriam Tarallo, Marco DiBonaventura, Danielle Bargo, James Lucas, Daniel Bluff, Ben Hoskin, Leonardo Salese, Joseph C. Cappelleri, Giovanni Gigante

Item 1 - 6 / 6
1